Large-scale testing (Phase 3)UnknownNCT06140186What this trial is testingEfficacy and Safety of Timolol for TKI Induced ParonychiaWho this might be right forParonychia Queen Mary Hospital, Hong Kong 40
Testing effectiveness (Phase 2)UnknownNCT04318223What this trial is testingPalbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal TherapyWho this might be right forMetastatic Breast CancerLocally Advanced Breast Cancer Consorzio Oncotech 168
Not applicableStudy completedNCT02285361What this trial is testingGIOTRIF rPMS in Korean Patients With NSCLCWho this might be right forCarcinoma, Non-Small-Cell Lung Boehringer Ingelheim 1,272
Testing effectiveness (Phase 2)UnknownNCT04034589What this trial is testingPyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46
Not applicableNot Yet RecruitingNCT07593196What this trial is testingHER2-positive Metastatic Breast Cancer in KazakhstanWho this might be right forMetastatic Breast Cancer AstraZeneca 240
Testing effectiveness (Phase 2)WithdrawnNCT00627627What this trial is testingEvaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast CancerWho this might be right forBreast Cancer MedImmune LLC 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT06198751What this trial is testingNeoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerWho this might be right forBreast Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 104
Early research (Phase 1)Study completedNCT01741727What this trial is testingABT-414 in Subjects With Solid TumorsWho this might be right forSquamous Cell Tumors AbbVie (prior sponsor, Abbott) 57
Large-scale testing (Phase 3)Ended earlyNCT06038539What this trial is testingEfficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast CancerWho this might be right forHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Biocon Biologics UK Ltd 55
Not applicableLooking for participantsNCT07143045What this trial is testingA Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) MetastasesWho this might be right forEGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases Alpha Biopharma (Jiangsu) Co., Ltd. 800
Large-scale testing (Phase 3)Study completedNCT02864251What this trial is testingNivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyWho this might be right forNon-Small-Cell Lung Carcinoma Bristol-Myers Squibb 367
Testing effectiveness (Phase 2)Study completedNCT00547157What this trial is testingRadiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and NeckWho this might be right forCancerHead and Neck CancerOncology+1 more Amgen 152
Testing effectiveness (Phase 2)Study completedNCT01973660What this trial is testingPAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast CancerWho this might be right forBreast Cancer SOLTI Breast Cancer Research Group 151
Early research (Phase 1)Ended earlyNCT03296696What this trial is testingStudy of AMG 596 in Patients With EGFRvIII Positive GlioblastomaWho this might be right forGlioblastoma or Malignant Glioma Amgen 30
Not applicableUnknownNCT02119559What this trial is testingCirculating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell CarcinomaWho this might be right forMetastatic Head-and-neck Squamous-cell Carcinoma University Hospital, Montpellier 115
Post-approval studies (Phase 4)Study completedNCT01609543What this trial is testingTarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR MutationsWho this might be right forNon-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche 62
Not applicableStudy completedNCT05905939What this trial is testingHER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in RussiaWho this might be right forBreast Cancer AstraZeneca 774
Testing effectiveness (Phase 2)Looking for participantsNCT05334277What this trial is testingFurmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNAWho this might be right forNon-small Cell Lung Cancer Sun Yat-sen University 280
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07287098What this trial is testingImlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerWho this might be right forBreast Neoplasms Eli Lilly and Company 600
Testing effectiveness (Phase 2)Study completedNCT01325428What this trial is testingAfatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast CancerWho this might be right forBreast Neoplasms Boehringer Ingelheim 26